Recent Articles
New: Be the first to
follow us on Twitter.


China Stocks

More Articles...

Consumer Stocks

More Articles...

Energy Stocks

More Articles...

ETFs & Mutual Funds

More Articles...

Global Investing

More Articles...

Gold & Materials Stocks

More Articles...

Income Investing

More Articles...

Industrial Stocks

More Articles...

Healthcare & Biotech

More Articles...

Technology Stocks

More Articles...

Todays Best Investment Ideas
Medical research: Small cap duo
Monday, April 13, 2009

 Small cap expert Jim Oberweis, Jr. looks to two medical stocks; in The Oberweis Report, he eyes one firm focused on venous reflex disease and another that is treating fibromyalgia.

"VNUS Medical Technologies (NASDAQ: VNUS) is a leading provider of medical devices for the minimally invasive treatment of venous reflux disease.

"This is a progressive condition caused by incompetent vein valves in the legs. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers and painful varicose veins.

"The company’s primary product line, the VNUS Closure system, consists of a proprietary radio-frequency, or RF, generator and proprietary disposable endovenous catheters to close diseased veins through the application of temperature-controlled RF energy.

"Historically, open surgery, such as vein stripping and ligation, has been the standard of care, but it is traumatic and can result in significant post-operative pain and extended recuperation. 

"The firm's Closure procedure is minimally invasive, can be used in an outpatient or physician office setting, and results in quicker recovery times.  In addition, the cost is normally reimbursable by insurance companies.

" In the company’s latest reported fourth quarter, sales increased approximately 32% to $27.2 million from $20.6 million in the fourth quarter of last year.

"VNUS Medical Technologies reported earnings per share of $.21 in the latest reported fourth quarter versus $.05 in the same quarter of last year.

"Please note that 2008 results include $8.7 million in royalty revenues recognized in the second quarter attributable to periods before 2008.

"Cypress Bioscience (NASDAQ: CYPB) is focused on developing products for the treatment of unmet medical needs including disorders such as fibromyalgia and rheumatoid arthritis.

"Its most recent success was receiving FDA approval in January 2009 for their drug Savella (milnacipran) to treat fibromyalgia. 

"Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body that is not the result of inflammation as with arthritis and other debilitating rheumatological disorders. 

"Fibromyalgia is estimated to affect over 6 million people in the US.  Forest Labs will co-promote the drug with Cypress, and a commercial launch is expected in March.

"The company’s recent financials have exhibited little growth and negative earnings per share, however following FDA approval for Savella in January of ’09 and an expected March launch, we expect the financials to change quite dramatically and show significant growth.

"Also note the company currently has $150 million in cash on the balance sheet, which equates to approximately $4 per share.

"Clients of Oberweis Asset Management own approximately 245,000 shares. of VNUS and approximately 750,000 shares of Cypress. Both stocks may be suitable for risk-oriented investors."

 

Newsletter News & Deals

Sign up now for our free Daily Newsletter



Meet the KCI editors

Join Roger Conrad, Gregg Early, Elliott Gue, and Yiannis Mostrous in San Diego on April 23-24. Call 1-800-832-2330 or go to www.InvestingSummit.com.

 
Dividend Still Don't Lie

Dividends Don't Lie -- by IQ Trends founder Geraldine Weiss -- is one of the all-time great investment books.

Now, editor Kelley Wright is following up this classic with Dividend Still Don't Lie, which can be ordered at a significant discount.

 
Keith Fitz-Gerald: Fiscal Hangover

Get a $10 discount on Keith's new book on global investing -- Fiscal Hangover. Click here.

 
Red, White & Bold

Global expert Carl Delfeld's new book -- Red, White & Bold -- is now available.

 
Gone Fishin' Portfolio

The Oxford Club's Alexander Green has released an exceptional new book-- The Gone Fishin' Portfolio -- which provides an all-weather approach to investing.

 
EconoPower

Mark Skousen's latest book, “EconoPower: How a New Generation of Economists is Transforming the World” (Wiley & Sons), is available for $16.47 (plus shipping) from Amazon.com (retail $24.95).

 
Guide to seasonal trading

Sy Harding has published Beat the Market the Easy Way -- an in-depth review of seasonal market patterns and their application to long-term timing.

 
Dick Davis Dividend

In The Dick Davis Dividend, the investing legend shares a lifetime of insights on investing.